Wall Street Wizardry
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Wall Street Wizardry

Politics

Trump amends executive order raising China tariffs to 20% over ‘failure to address’ fentanyl crisis

by admin March 4, 2025
March 4, 2025
Trump amends executive order raising China tariffs to 20% over ‘failure to address’ fentanyl crisis

The White House announced Monday that China will face increased tariffs, citing the ongoing fentanyl crisis in the U.S. as the main reason for the decision.

In a post on X, the Rapid Response 47 account shared the text of an executive order (EO) signed by President Donald Trump on Monday. The Chinese government will now face 20% tariffs ‘over their failure to address the fentanyl pouring into our country,’ the EO stated.

The tariffs against China, which were originally only 10%, will go into effect on Tuesday. In Monday’s order, Trump said that the Chinese government has failed ‘to blunt the sustained influx of synthetic opioids, including fentanyl, flowing from [their country],’ and that such failure constitutes an ‘unusual and extraordinary threat.’

Trump also said that the crisis jeopardizes the ‘national security, foreign policy, and economy of the United States.’

‘I have determined that the [People’s Republic of China] has not taken adequate steps to alleviate the illicit drug crisis through cooperative enforcement actions, and that the crisis described in Executive Order 14195 has not abated,’ the order read. 

‘In recognition of the fact that the PRC has not taken adequate steps to alleviate the illicit drug crisis, section 2(a) of Executive Order 14195 is hereby amended by striking the words ‘10 percent’ and inserting in lieu thereof the words ‘20 percent’.’

The Trump administration is already imposing 25% tariffs on Canadian and Mexican goods, which were announced last month and will also go into effect on Tuesday. On Monday, Peter Navarro, the White House senior counselor on trade and manufacturing, defended the tariffs to CNBC and argued that the issue ‘starts in communist China with the precursor chemicals.’

‘It comes into Mexico, and they make the fentanyl. But they also have these pill presses. So they do the counterfeits,’ Navarro explained. ‘And they’re using Canada as a transit hub and secondary point to manufacture as well. So this is a Canada-Mexico-China thing.’

The Chinese government has opposed the tariffs since they were announced. In a Feb. 1 statement, China’s Ministry of Foreign Affairs claimed that China is ‘one of the world’s toughest countries on counternarcotics both in terms of policy and its implementation.’

‘Additional tariffs are not constructive and bound to affect and harm the counternarcotics cooperation between the two sides in the future,’ the statement read. ‘China calls on the U.S. to correct its wrongdoings, maintain the hard-won positive dynamics in the counternarcotics cooperation, and promote the steady, sound and sustainable development of China-U.S. relationship.’

Fox News Digital’s Anders Hagstrom contributed to this report.

This post appeared first on FOX NEWS

previous post
Theme of Trump’s address to Congress revealed
next post
Workers survive 36 hours buried under India avalanche

Related Posts

Experts warn Iran’s nuclear double-talk designed to buy...

April 5, 2025

Hamas terrorists torture protester to death in Gaza,...

April 1, 2025

Direct aid to Israel should be phased out...

March 14, 2025

Trump-backed bills on activist judges, non-citizen voting heading...

April 8, 2025

Voters widely oppose taxpayer-funded gender surgeries, revealing Democrat...

April 15, 2025

Trump has not directed administration to declassify Biden...

May 23, 2025

Top Republican warns families of ‘largest tax hike...

April 16, 2025

Trump makes endorsement in ‘important’ Wisconsin Supreme Court...

March 24, 2025

‘Too aggressive militarily’: Trump talks Hegseth’s role pardoning...

March 4, 2025

South African-born Musk evoked by Trump during meeting...

May 22, 2025

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 2

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 3

      US security contractor will take charge of key checkpoint in Gaza as Israeli forces withdraw

      January 25, 2025
    • 4

      Trump re-designates Iranian-backed Houthis as terrorists: ‘Threaten[s] security of American civilians’

      January 23, 2025
    • 5

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 6

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • 7

      Universal’s ‘Wicked: For Good’ creates a unique marketing challenge

      January 26, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: wallstreetwizardry.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 wallstreetwizardry.com | All Rights Reserved